Benjamin A. Nacev

University of Pittsburgh — United States

Medicine · Health Sciences

21h-index2.1kcitations150works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(76), Cancer Immunotherapy and Biomarkers(51), Histone Deacetylase Inhibitors Research(22), Lung Cancer Treatments and Mutations(20), CAR-T cell therapy research(19)

Publications150 total

First Report of Primary Mesenchymal Chondrosarcoma of the Urinary Bladder
International Journal of Surgical Pathology·2026Open Access
Perioperative Management of Targeted and Immunologic Agents in Neurosurgical Oncology
Neurosurgery·2026
ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival
ESMO rare cancers.·2026
Supplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
Supplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
2025Open Access
ATRX loss in sarcomas is associated with dysregulated gene and transposable element expression, loss of DNA methylation, and worse survival
2025Open Access
High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy
Journal for ImmunoTherapy of Cancer·2025Open Access
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma
ESMO Open·2025· 1 citedOpen Access
Predicting transposable element-derived neoantigens in ATRX-mutated sarcoma.
Journal of Clinical Oncology·2025
Methylation Analysis Reveals Epigenetic Congruence Between Bone Sarcomas With H3-3A Mutations and Malignant Giant Cell Tumors of Bone
Modern Pathology·2025· 1 cited
50 Validation and Clinical Application of Whole Transcriptome RNA Sequencing Assay in the Diagnosis of Soft Tissue Neoplasms
Laboratory Investigation·2025Open Access
ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
JCO oncology advances.·2025· 2 citedOpen Access
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models
Journal of Clinical Investigation·2024· 12 citedOpen Access
Detection of Alternative Lengthening of Telomeres via Chromogenic In Situ Hybridization for the Prognostication of PanNETs and Other Neoplasms
Modern Pathology·2024· 5 citedOpen Access
Author Correction: Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiation
Nature Communications·2024Open Access
Supplementary Data 2 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
2024Open Access
Supplementary Data 1 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
2024Open Access
Supplementary Data 1 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
2024Open Access
Supplementary Data 3 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
2024Open Access
page 1 of 8Next →

Frequent Co-authors

William D. Tap(28), Mark A. Dickson(23), Mrinal M. Gounder(22), Sandra P. D’Angelo(22), Evan Rosenbaum(21), Ping Chi(21), Ciara M. Kelly(21), Sujana Movva(18), Mary Louise Keohan(17), Samuel Singer(15), Cristina R. Antonescu(14), Li‐Xuan Qin(14), Katherine A. Thornton(13), Jason E. Chan(12), Jun O. Liu(11), Sinchun Hwang(11), Viswatej Avutu(10), Emily K. Slotkin(8), Mark T.A. Donoghue(8), Aimeé M. Crago(7)